Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933056 | 1.00 | CNR2 (0.42) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL6543483 | 1.00 | CNR2 (0.42) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL1852711 | 1.00 | CNR2 (0.42) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL7905480 | 1.00 | CNR2 (0.42) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL7911980 | 1.00 | CNR2 (0.42) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL11400432 | 0.98 | CNR2 (0.41) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL1866342 | 0.94 | CNR2 (0.40) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL8754397 | 0.86 | SLC18A3 (0.43) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL7750595 | 0.86 | PTGS2 (0.41) | CNR2NPY1RHTTNPY2RCNR1 | |
| SCHEMBL30207528 | 0.80 | SLC6A4 (0.59) | CNR2OPRM1OPRL1SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0168949-B2 | Microbiocidal compositions and processes for imparting microbiocidal properties to polymer compositions | THIOKOL MORTON INC (US) | 1995-06-14 | — | — | EP | claimed |
| US-5420366-A | Hydrogenolysis | HOECHST CELANESE CORPORATION (US) | 1995-05-30 | — | — | US | claimed |
| US-8828902-B2 | Microencapsulated catalyst methods of preparation and method of use thereof | REAXA LIMITED (GB) | 2014-09-09 | — | — | US | disclosed |
| US-8828902-B2 | Microencapsulated catalyst methods of preparation and method of use thereof | REAXA LIMITED (GB) | 2014-09-09 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| US-6197994-B1 | PREPARING VICINAL DIOLS BY CATALYTIC ASYMMETRIC DIHYDROXYLATION OF OLEFINS USING SILICA GEL SUPPORTED BIS-CINCHONA ALKALOID DERIVATIVE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2001-03-06 | — | — | US | disclosed |
| US-5968867-A | REUSABLE CATALYSTS FOR DIHYDROXYLATION OF OLEFINS TO OPTICALLY-ACTIVE VICINAL DIOLS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1999-10-19 | — | — | US | disclosed |
| US-5420366-A | Hydrogenolysis | HOECHST CELANESE CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | CNR2 690/4885NPY1R 103/4885HTT 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.